Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Angina Pectoris Drugs Market - Forecast to Grow at a CAGR of 6.7% During 2017-2023 - Research and Markets

Research and Markets
Posted on: 27 Dec 17

The "Angina Pectoris Drugs - Global Market Outlook (2017-2023)" report has been added to Research and Markets' offering.

The Global Angina Pectoris Drugs Market accounted for $8501.3 million in 2016 and expected to grow at a CAGR of 6.7% to reach $13441.0 million by 2023. The market factors such as sedentary lifestyle and obesity in young generation, research and developments for effective drugs, high demand for target specific and tailored drugs for angina pectoris treatment and in developing countries the awareness related to cardiovascular diseases is increasing which in turn is driving market growth. Further market will witness few trends such as introduction of new pharmacologic agents, Genomic medicines and growing trend of strategic alliances and acquisitions.

Adrenoceptor antagonists (-blockers) are recommended for the firsto line treatment of heart failure, coronary artery disease, and atrial fibrillation as well as of hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. -Blocker therapy should als-be considered in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to improve efforto related angina symptoms. According to The British journal of Cardiology, chronic stable angina pectoris affects around 2 - 4% of the population in western countries and it is associated with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1-2% and 3% respectively.

Current European and North American guidelines advise continuing dual antiplatelet therapy for 1 year following an acute coronary syndrome. Cangrelor is a novel P2Y12 inhibitor that, like ticagrelor, binds directly to the receptor and induces reversible blockade. The drug is a nonthienopyridine adenosine triphosphate analogue that is administered intravenously and has shown promising results in clinical trials to date. bciximab (a monoclonal antibody fragment), tirofiban (a small, non-peptide molecule) and eptifibatide (a cyclic heptapeptide derived from rattlesnake venom) are used in clinical practice.

Companies Mentioned

  • Astellas Pharma
  • Cardium Therapeutics
  • Cardeus Pharmaceuticals
  • CardioVascular BioTherapeutics (CVBT)
  • Ark Therapeutics Group plc
  • HUYA Bioscience International LLC
  • Bristol-Myers Squibb Company

Key Topics Covered:

1. Executive Summary

2. Preface

3. Market Trend Analysis

4. Porters Five Force Analysis

5. Global Angina Pectoris Drugs Market, By Drug Class

6. Global Angina Pectoris Drugs Market, By End User

7. Global Angina Pectoris Drugs Market, By Geography

8. Key Developments

9. Company Profiles

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.